Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Revolution Medicines is a clinical-stage precision oncology company focused on inhibiting RAS-addicted cancers. The Senior Director of Patient Reported Outcomes (PROs) will lead the strategy and execution of PROs within the company's R&D pipeline, focusing on integrating them into clinical development, regulatory submissions, and market access strategies. This role will play a critical part in shaping the future of patient care in Oncology.
Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Revolution Medicines